Stryker Corporation
SYK
$310.00
+1.74%
Stryker Corporation is a leading global medical technology company that designs, manufactures, and markets a diverse portfolio of medical equipment, instruments, consumable supplies, and implantable devices. The company holds a dominant market position as one of the three largest competitors in reconstructive orthopedic implants and is the leader in operating room equipment, with key segments including Orthopaedics and MedSurg. The current investor narrative is shaped by its strategic expansion through acquisitions, such as the recent Amplitude Vascular Systems deal to bolster its peripheral vascular portfolio, and the ongoing debate around its ability to sustain growth and margins amidst a challenging macroeconomic environment that has pressured its stock price relative to the broader market.…
SYK
Stryker Corporation
$310.00
Related headlines
Investment Opinion: Should I buy SYK Today?
Rating: Hold. The core thesis is that Stryker is a fundamentally strong company caught in a negative momentum cycle, making it a Hold for existing investors but requiring a more attractive entry point for new buyers.
Supporting Evidence: The Hold rating is anchored by the significant 39% upside to the analyst consensus target (~$427), the reasonable forward P/E of 18.4x based on expected earnings growth, and the company's exceptional financial health evidenced by $4.28B in TTM FCF and a 19.47% operating margin. However, these positives are counterbalanced by the severe technical damage (stock down 17.54% YoY, near 52-week low), the rich trailing P/E of 41.38x, and the high PEG ratio of 5.16 which signals elevated growth expectations.
Risks & Conditions: The two biggest risks are 1) failure to meet the high forward earnings expectations, triggering multiple compression, and 2) a breakdown below $281 support, extending the downtrend. This Hold would upgrade to a Buy if the stock stabilizes above $300 and shows evidence of the earnings acceleration materializing (e.g., QoQ EPS growth confirming the forward estimates), or if it falls to the $280-$290 range, offering a higher margin of safety. It would downgrade to a Sell if forward EPS estimates are revised down by 5% or more, or if $281 support fails on a weekly closing basis. Relative to its own history and the growth implied, the stock is fairly valued to slightly overvalued on a trailing basis but appears reasonably valued if forward estimates are achieved.
Sign up to view all
SYK 12-Month Price Forecast
The AI assessment is neutral based on the high-conviction clash between compelling fundamentals and broken technicals. The company's financial engine is powerful, but the stock's momentum is profoundly negative. The high probability base case (50%) reflects a belief that Stryker will execute operationally but may struggle to regain investor favor quickly, leading to a choppy, range-bound recovery. The stance would upgrade to bullish on a confirmed weekly close above the $350 resistance level, signaling a technical reversal. It would downgrade to bearish on a weekly close below $281, confirming the downtrend's continuation.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Stryker Corporation's 12-month outlook, with a consensus price target around $403.00 and implied upside of +30.0% versus the current price.
Average Target
$403.00
11 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
11
covering this stock
Price Range
$248 - $403
Analyst target range
Stryker is covered by 11 analysts, indicating substantial institutional research interest. The consensus recommendation leans bullish, as evidenced by recent actions from firms like Needham, BTIG, Bernstein, and Citigroup maintaining Buy or Outperform ratings, while UBS and Truist maintain Neutral/Hold stances. The average target price implied by the estimated EPS of $23.19 and a forward P/E of 18.4 suggests a consensus price target of approximately $427, which would imply a significant upside of roughly 39% from the current price of $307.8. The target range is derived from estimated EPS lows of $22.79 and highs of $23.48, indicating relatively tight clustering and high conviction in near-term earnings. The high-end target likely assumes successful integration of acquisitions, market share gains, and multiple expansion, while the low-end target may factor in potential macroeconomic pressures, pricing headwinds, or slower-than-expected growth. The recent ratings activity shows stability, with no major downgrades in the provided data, suggesting analyst confidence in the company's long-term strategy despite recent stock price weakness.
Bulls vs Bears: SYK Investment Factors
The investment debate for Stryker centers on a stark divergence between deteriorating price action and resilient, high-quality fundamentals. The bear side currently presents stronger near-term evidence, as the stock is in a severe downtrend, trades near 52-week lows, and carries a rich trailing valuation. However, the bull case is compellingly grounded in expected earnings acceleration, robust cash flow, and a significant 39% analyst upside. The single most important tension is whether the company can deliver the substantial earnings growth (implied by the forward P/E of 18.4x) necessary to justify its valuation and reverse the powerful negative technical momentum. The resolution of this tension—through upcoming earnings reports and guidance—will dictate the stock's direction.
Bullish
- Strong Forward Earnings Growth: The forward P/E of 18.4x is significantly lower than the trailing P/E of 41.38x, indicating analysts expect a substantial 120%+ increase in earnings over the next year. This expectation is supported by a consensus EPS estimate of $23.19, implying robust profit growth from the current quarterly run-rate.
- Robust Cash Generation and Financial Health: Stryker generates massive free cash flow, with TTM FCF of $4.283 billion, supporting a healthy dividend (payout ratio 39.56%) and strategic acquisitions. The balance sheet is solid with a debt-to-equity ratio of 0.73 and a current ratio of 1.89, providing ample liquidity and financial flexibility.
- Resilient Revenue and High Margins: Q4 2025 revenue grew 11.42% YoY to $7.171B, demonstrating resilient demand. The company maintains premium profitability with a gross margin of 65.22% and an operating margin of 19.47%, reflecting strong pricing power and operational efficiency in its dominant market positions.
- Significant Analyst Upside Potential: The consensus analyst price target implied by forward EPS is approximately $427, representing a 39% upside from the current price of $307.8. This bullish sentiment is reinforced by 11 covering analysts, with several maintaining Buy/Outperform ratings despite recent stock weakness.
Bearish
- Severe Technical Downtrend and Underperformance: The stock is down 17.54% over the past year, dramatically underperforming the S&P 500's 24.99% gain, with a maximum drawdown of -29.97%. Trading near its 52-week low of $281, it shows persistent selling pressure and negative momentum, with relative strength figures deeply negative.
- Rich Valuation on Trailing Metrics: The trailing P/E of 41.38x is elevated, and the PEG ratio of 5.16 suggests the stock is expensive relative to its historical growth. This high multiple leaves the stock vulnerable to valuation compression if forward earnings growth disappoints or market sentiment sours further.
- High Expectations Embedded in Forward Multiple: The entire bullish thesis hinges on the company delivering on the aggressive earnings growth implied by the forward P/E of 18.4x. Any stumble in revenue growth (currently 11.42% YoY) or margin pressure could trigger significant estimate revisions and multiple contraction.
- Sector and Macro Headwinds: The stock's significant underperformance, despite a low beta of 0.785, points to company or sector-specific challenges. Potential headwinds include procedure volume pressures, pricing negotiations with hospital customers, and a higher cost of capital impacting valuation for acquisitive growth.
SYK Technical Analysis
Stryker's stock is in a sustained downtrend over the past year, with a significant 1-year price change of -17.54%, sharply underperforming the S&P 500's 24.99% gain. The current price of $307.8 positions it at approximately 11% of its 52-week range ($281 to $404.87), indicating it is trading much closer to its 52-week low, which could signal a potential value opportunity but also reflects persistent selling pressure and negative market sentiment. The stock's beta of 0.785 suggests it has been less volatile than the market, yet its severe underperformance highlights significant company-specific or sector-specific headwinds. Recent momentum remains weak, with the stock down 3.13% over the past month and 8.30% over the past three months, confirming the continuation of the longer-term downtrend. The negative relative strength figures, such as -42.53 over one year and -23.44 over three months, underscore a consistent lack of buying interest compared to the market. The price action shows a significant breakdown from the $350-$380 range in March 2026, leading to a sharp decline to a low near $282 in May, with a subsequent modest recovery that has so far failed to reclaim key moving averages. Key technical support is clearly defined at the 52-week low of $281, while resistance lies at the recent breakdown zone around $350 and the 52-week high of $404.87. A break below $281 would signal a further bearish acceleration, while a sustained move above $350 would be needed to suggest a potential trend reversal. The stock's maximum drawdown of -29.97% over the provided period illustrates the magnitude of recent downside volatility, emphasizing the importance of the $281 support level for the near-term technical picture.
Beta
0.79
0.79x market volatility
Max Drawdown
-30.0%
Largest decline past year
52-Week Range
$281-$405
Price range past year
Annual Return
-18.2%
Cumulative gain past year
| Period | SYK Return | S&P 500 |
|---|---|---|
| 1m | -2.0% | -1.6% |
| 3m | -5.4% | +11.7% |
| 6m | -12.6% | +6.3% |
| 1y | -18.2% | +22.2% |
| ytd | -11.0% | +7.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
SYK Fundamental Analysis
Stryker's revenue trajectory remains positive, with the most recent Q4 2025 quarterly revenue of $7.171 billion representing a solid 11.42% year-over-year growth. The quarterly sequence from Q1 2025 ($5.866B) to Q4 2025 ($7.171B) shows consistent sequential growth, driven by both its Orthopaedics ($4.964B) and MedSurg ($4.562B) segments. This indicates resilient demand for its medical devices, though the growth rate is decelerating from the higher rates seen in prior comparable periods. The company is solidly profitable, reporting Q4 2025 net income of $849 million, translating to a net margin of 11.84%. Gross margins are robust at 65.22% for the quarter, and the trailing twelve-month operating margin stands at 19.47%, reflecting strong pricing power and operational efficiency typical of leading medical device firms. Profitability metrics are healthy, with a return on equity (ROE) of 14.48% and return on assets (ROA) of 7.72%. The balance sheet and cash flow position is strong, with a current ratio of 1.89 and a debt-to-equity ratio of 0.73, indicating manageable leverage. Critically, the company generates substantial free cash flow, with TTM free cash flow of $4.283 billion, providing ample internal funding for growth initiatives, dividends (payout ratio of 39.56%), and strategic acquisitions like the recent Amplitude Vascular Systems deal. The strong cash generation, evidenced by a free cash flow yield of approximately 3.2% based on market cap, underpins the company's financial stability and capacity for shareholder returns.
Quarterly Revenue
$7.2B
2025-12
Revenue YoY Growth
+0.11%
YoY Comparison
Gross Margin
+0.65%
Latest Quarter
Free Cash Flow
$4.3B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is SYK Overvalued?
Given Stryker's consistent profitability (Net Income > 0), the primary valuation metric is the Price-to-Earnings (P/E) ratio. The trailing P/E ratio is elevated at 41.38x, while the forward P/E is significantly lower at 18.40x, indicating the market expects a substantial rebound in earnings growth over the next twelve months. Compared to its historical P/E range observed in the data, which has fluctuated between approximately 25x and 62x over recent years, the current trailing multiple is above the midpoint, suggesting the stock is not cheap on a trailing basis but may be reasonably valued if forward earnings estimates materialize. The stock trades at a Price/Sales (P/S) ratio of 5.35x and an EV/Sales of 5.20x. While direct industry average multiples are not provided in the data, the premium implied by the forward P/E likely reflects Stryker's market leadership, strong margins, and consistent execution. The significant gap between trailing and forward P/E underscores high market expectations for earnings acceleration, leaving the stock vulnerable to estimate revisions. The PEG ratio of 5.16, based on trailing metrics, suggests the stock is richly priced relative to its historical growth, further emphasizing that future performance is already being discounted.
PE
41.4x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 23x~78x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
23.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Stryker's primary financial risk is valuation, not solvency. The company's high trailing P/E of 41.38x and PEG ratio of 5.16 indicate the market has priced in exceptional future growth. Should revenue growth decelerate from the current 11.42% YoY pace or should net margins fail to expand toward the implied forward earnings, significant multiple compression is likely. While the balance sheet is strong (D/E 0.73), the company's acquisitive growth strategy carries integration and overpayment risks, as seen with the recent Amplitude Vascular deal. Dependence on a successful capital deployment strategy to drive growth is a key operational risk.
Market & Competitive Risks: The stock faces pronounced market risks related to its premium valuation. Trading at a forward P/E of 18.4x, which is reasonable only if high growth is achieved, it remains vulnerable to sector-wide de-rating if interest rates stay elevated, compressing valuations for growth-oriented healthcare stocks. Competitive intensity in orthopedics and med-surg is constant, and pricing pressure from hospital group purchasing organizations could threaten the robust 65.22% gross margin. The stock's low beta of 0.785 has not protected it from severe underperformance (-42.53 relative strength vs. S&P), indicating potent company-specific negative sentiment that may persist.
Worst-Case Scenario: The worst-case scenario involves a combination of an earnings miss, a guidance cut, and a breakdown of key technical support. This could unfold as Q1 2026 results show slowing procedure volumes and margin contraction, leading analysts to slash forward EPS estimates from $23.19 toward the low end of $22.79. Concurrently, the stock breaks decisively below the $281 support level, triggering algorithmic and stop-loss selling. In this adverse scenario, the stock could re-test prices 35-40% below current levels, aligning with a bear-case P/E in the low teens applied to reduced earnings, implying a realistic downside to the $180-$220 range from the current $307.8.
FAQ
The key risks are: 1) Valuation & Execution Risk: The high forward earnings expectations (implied by the P/E drop from 41.38x to 18.4x) may not be met, leading to a sharp price decline. 2) Technical/Momentum Risk: The stock is in a severe downtrend, down 17.54% YoY, and a break below $281 support could accelerate losses. 3) Competitive/Market Risk: Pricing pressure in the medical device sector could erode the premium 65.22% gross margin. 4) Acquisition Risk: The company's growth-via-M&A strategy carries integration and overpayment risks, as seen with recent deals.
The 12-month forecast is scenario-based. The Base Case (50% probability) sees the stock trading between $340 and $400 as it meets earnings estimates and stages a modest recovery. The Bull Case (30% probability) targets $404 to $450, driven by earnings beats and multiple expansion. The Bear Case (20% probability) warns of a drop to the $281 to $320 range if growth disappoints and support breaks. The most likely scenario is the Base Case, predicated on the assumption that Stryker delivers its consensus EPS of $23.19 but continues to grapple with negative investor sentiment.
SYK's valuation is bifurcated. On a trailing basis, with a P/E of 41.38x and a PEG of 5.16, it appears overvalued relative to its recent growth. However, the forward P/E of 18.4x, based on expected EPS of $23.19, suggests the stock is fairly valued or even slightly undervalued if that growth materializes. Compared to its own historical P/E range (25x-62x), the current trailing multiple is above the midpoint. The market is currently paying a fair price for very high expected future earnings growth, making the stock vulnerable to being overvalued if those expectations are not met.
SYK presents a complex risk/reward profile. For new investors, it is not an unequivocal 'good buy' at this moment due to its strong downtrend and location near 52-week lows. However, for patient, value-oriented investors willing to average in, the 39% upside to analyst targets and reasonable forward P/E of 18.4x are attractive. The biggest downside risk is a break below $281 support, which could lead to another 10-15% decline. It is a good buy for long-term holders who believe in the fundamental story and can tolerate volatility, but short-term traders should await a clearer technical reversal signal.
SYK is unequivocally more suitable for a long-term investment horizon of 3+ years. Its low beta (0.785) and strong dividend (payout ratio 39.56%) support a buy-and-hold approach, allowing investors to collect income while waiting for the fundamental story to overcome technical headwinds. The stock's high earnings visibility and market leadership are long-term strengths. It is poorly suited for short-term trading due to its persistent negative momentum and vulnerability to sharp downdrafts on any earnings-related news. A minimum holding period of 18-24 months is suggested to allow the forward earnings growth narrative to play out.